Regulatory News:

STENTYS (FR0010949404 — STNT), a medical technology company commercializing the world's first and only Self-Apposing® coronary stent, today announces that the first interventions using its self-expanding drug-eluting stent to treat BTK (below-the-knee) arterial disease have been performed during two live-case sessions broadcasted during LINC, the Leipzig Interventional Course, the largest congress on peripheral pathologies.

The two procedures on patients suffering from critical lower-limb ischemia (CLI) were performed by the Leipzig University Hospital angiology team (Dr. Andrej Schmidt, Dr. Sven Bräunlich, Dr. Matthias Ulrich). Several overlapping STENTYS stents were successfully implanted to treat the long lesions of the leg arteries.

Gonzague Issenmann, Chief Executive Officer and co-founder of STENTYS, comments: “These first two procedures outside of a clinical trial went perfectly well, and the final results were unanimously acclaimed by the members of the panel of experts who moderated the cases. The physicians were delighted to learn that they can now treat their patients with a drug-eluting and self-expanding stent, the first available for this indication in Europe.”

About STENTYS

STENTYS is developing and commercializing innovative solutions for the treatment of patients with complex coronary artery disease. STENTYS’ Self-Apposing® Stents are designed to adapt to vessels with ambiguous or fluctuating diameters in order to prevent the malapposition problems associated with conventional stents. The APPOSITION clinical trials in the treatment of acute myocardial infarction showed a very low one year mortality rate and a faster arterial healing compared to conventional stents. The company’s product portfolio also includes MiStent SES®, a coronary DES whose new drug delivery mechanism is designed to match vessel response, and is marketed through STENTYS’ commercial network in Europe, the Middle East, Asia and Latin America. More information is available at www.stentys.com.

Safe Harbor Statements

This press release contains forward-looking statements about the Company that are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which it will operate in the future which may not be accurate. Such forward-looking statements involve known and unknown risks which may cause the Company’s actual results, performance or achievements to differ materially from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, among others, risks associated with the development and commercialization of the Company’s products, market acceptance of the Company’s products, its ability to manage growth, the competitive environment in relation to its business area and markets, its ability to enforce and protect its patents and proprietary rights, uncertainties related to the U.S. FDA approval process, slower than expected rates of patient recruitment for clinical trials, the outcome of clinical trials, and other factors, including those described in the Section 4 “Risk Factors” of the Company’s 2014 Registration Document (document de référence) filed with the French Autorité des Marchés Financiers on July 29, 2015 under number D.15-0807 as such section may be updated from time to time.

STENTYS is listed on Comp. C of the Euronext Paris market

ISIN: FR0010949404 – Ticker: STNT